Xcout Intel
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Subscribe to see TransCode Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
TransCode Therapeutics, Inc. at a glance
TransCode Therapeutics, Inc. is a biotech company headquartered in Boston, United States. It is publicly listed (RNAZ) with a market capitalisation of $3.3M. Xcout tracks 25 named people at TransCode Therapeutics, Inc., including Philippe Calais (Chief Executive Officer & Executive Chairman of the Board).
TransCode Therapeutics, Inc. leadership
- Philippe CalaisChief Executive Officer & Executive Chairman of the Board
- Philippe P CalaisChairman and CEO
- Thomas A. FitzgeraldCFO, Secretary, President, VP of Administration & Director
- John A. TattoryInterim Chief Financial Officer
- Tom FitzgeraldCFO
- Daniel R. VlockChief Medical Officer
19 more named people on record for TransCode Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
TransCode Therapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | Undisclosed | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
TransCode Therapeutics, Inc. competitors
A few of TransCode Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
TigaTx is a Boston-based biotechnology company founded in 2018 that is developing a pipeline of therapies targeting various cancer types and infectious diseases.
HelixNano is a biotechnology research company headquartered in Boston, Massachusetts, focused on developing advanced mRNA platform technologies for therapeutics.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
ReCode Therapeutics is a clinical-stage genetic medicines company headquartered in Menlo Park, California, and Durham, North Carolina. The company leverages proprietary delivery systems to power a new class of disease-modifying genetic therapies.
Kernal Biologics is an onco-selective mRNA therapeutics company located in Cambridge, Massachusetts, that creates mRNA therapies designed to instruct specific cells on how to make proteins.
Tessera Therapeutics is a biotechnology company developing programmable genetic medicines using its Gene Writing technology, which is based on mobile genetic elements to insert, replace, or modify DNA in cells. It aims to develop treatments for genetic diseases and other serious conditions, serving patients who need durable genetic therapies.
Get TransCode Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on TransCode Therapeutics, Inc. in Xcout Intel
- 25 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access